Mizuho sets USD 0.50 target for EyePoint Pharmaceuticals stock
Published on 10/27/2026 at 22:37 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSMizuho confirms a USD 0.50 target
- Mizuho reaffirmed a Neutral rating and set a USD 0.50 target on October 20, 2026.
- EyePoint reported USD 0.51 million in second-quarter 2026 revenue and a USD 1.09 adjusted earnings-per-share loss.
- EyePoint stock last traded at USD 0.36 on Nasdaq on October 27, 2026 at 4:00 p.m. ET.
EyePoint Pharmaceuticals (ISIN US30233G2093) received a USD 0.50 price target from Mizuho on October 20, 2026, while the research firm reaffirmed its Neutral rating, according to MarketBeat. The target is 38.89 percent above the latest Nasdaq quote of USD 0.36.
EyePoint stock last traded at USD 0.36 on October 27, 2026 at 4:00 p.m. ET in after-hours data. The company had a market capitalization of USD 30.5 million at that time, giving the analyst target a substantially higher valuation reference than the current quote.
EyePoint narrows its development focus
EyePoint announced strategic prioritization on October 19, 2026, according to the company's EyePoint investor-relations page. The company said its late-stage DURAVYU program for diabetic macular edema would receive the central development focus after recent clinical setbacks.
Stock remains at its yearly low
The October 27, 2026 Nasdaq quote of USD 0.36 matched EyePoint's 52-week low and stood USD 18.75 below its 52-week high of USD 19.11. The range underscores the scale of the stock's recent repricing, while the current market capitalization was USD 30.5 million.
Second-quarter results set the baseline
For the second quarter of 2026, EyePoint reported revenue of USD 0.51 million and an adjusted loss of USD 1.09 per share, compared with analyst estimates of USD 0.45 million in revenue and a USD 1.01 per-share loss, according to MarketBeat. Revenue exceeded the estimate by USD 0.06 million, while the per-share loss was USD 0.08 wider than expected.
EyePoint is a biotechnology company focused on retinal therapies. Its lead product candidate, DURAVYU, is in Phase 3 trials for wet age-related macular degeneration and diabetic macular edema, according to the company's investor-relations page.
Market position and investor reference
The latest analyst view places the USD 0.50 target 38.89 percent above the USD 0.36 Nasdaq quote. That comparison puts the target in the context of a stock priced at its 52-week low, while the October 19 strategic prioritization supplies the company's current operating focus.
Market context: Market report S&P 500.
